Christian Angermayer: Investing in the Therapeutic Potential for Psychedelics

Published on
June 25th, 2021
Duration
68 minutes

The Real Titans of Finance: Demystifying the World of Prop Traders and Market Makers


Christian Angermayer: Investing in the Therapeutic Potential for Psychedelics

Mike Green in Conversation ·
Featuring Christian Angermayer and Michael Green

Published on: June 25th, 2021 • Duration: 68 minutes

Christian Angermayer, founder of Apeiron Investments, Atai Life Sciences, and COMPASS Pathways, made headlines for attributing his decision to invest in Bitcoin to a trip on mushrooms, but his journey as an investor and advocate for psychedelics goes much deeper than the clickbait. In this interview with Mike Green, Angermayer discusses how he went from a successful investor living the straight edge life to founding and eventually IPOing two startups, which are at the cutting edge of research into how mushrooms and other psychedelics could revolutionize the way we think about treating mental health issues. Together, they discuss the parallels between the modern human experience and other times of great change, how this is manifesting itself in societal and individual angst, and why this might make today the perfect time for broader acceptance of these treatments. They also touch on Green's own personal experience with mushrooms and Angermayer's optimistic approach to investing in technologies driving human progress. Filmed on May 8, 2021.